Episode Details

Revolution Medicines Daraxonrasib Pill Doubles Pancreatic Cancer Survival: A Game-Changing Breakthrough

Revolution Medicines late-stage trial results for their oral pill daraxonrasib show a significant improvement in pancreatic cancer survival. Patients taking the once-daily drug had a median survival of 13.2 months, doubling the 6.7 months from standard IV chemo. The pill targets RAS mutations driving over 90% of pancreatic tumors, showing promise for a wide range of patients. The news sent shares soaring, with analysts estimating a $10 billion market opportunity. The company plans to file with the FDA for quicker review and is considering acquisition offers.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/04175bf01d2e9bd1